Magnetic brain zaps may quiet anxiety: device trial puts it to the test
NCT ID NCT07819773
First seen Sep 15, 2026 · Last updated Sep 18, 2026 · Updated 2 times
Summary
Researchers are testing whether an accelerated protocol of transcranial magnetic stimulation using the BTL-699-2 device can reduce anxiety symptoms in adults with generalized anxiety disorder. The trial enrolls 40 adults aged 22 and older who receive 16 stimulation sessions over about four weeks, delivered twice per visit. Half receive active stimulation and half receive a sham treatment, and researchers compare anxiety scores three months after treatment ends to see if the active stimulation helps.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- transcranial magnetic stimulation with the BTL-699-2 device
- What this could lead to
- If it works, this could offer a non-invasive, drug-free option for people whose generalized anxiety disorder has not responded well to standard treatments.
- What could go wrong
- This is a small, early study of 40 people, and brain stimulation for anxiety is still experimental. The sham-controlled design means some participants receive inactive stimulation, and results may not hold up in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 22 years * A diagnosis of GAD according to DSM-5 criteria, confirmed by a qualified clinician at screening * Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb * Subjects willing and able to abstain from partaking in any treatments other than the pre-procedure therapy regime for the treatment of anxiety, including non-invasive brain stimulation treatments other than the study procedure during study participation * Willingness to comply with study instructions and to return to the clinic for the required visits * Women of child-bearing potential\* are required to use birth control measures during the whole duration of the study * If applicable, subjects must be maintained on their pre-study psychotherapeutic regimen and any prescribed chronic medications at a stable therapeutic dose for ≥4 weeks prior to enrollment, with no dose or usage frequency changes permitted during the study * Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Exclusion Criteria: * Metallic objects in or near the head rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or within 12 in (30 cm) of the treatment coil.\* * Implanted stimulator devices * Active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, ocular implants and vagus nerve stimulators. Contraindicated use could result in serious injury or death. * Drug pumps * Application in the heart area * Persons with a tendency to seizure (e.g., persons suffering from hypotonia and epilepsy) * Anticoagulation therapy * Severe or life-threatening condition * Pulmonary insufficiency * Heart disorders * Renal insufficiency * Decompensated\*\* hemorrhagic conditions * Decompensated\*\* blood coagulation disorders * Decompensated\*\* cardiovascular diseases * Malignant tumor or benign tumor * Fever * Pregnancy * Active suicidal intent\*\*\* * History of suicide attempts in the last 3 years * History or concurrent use of electroconvulsive therapy or vagus nerve stimulation * Substance-induced depression or depression secondary to a general medical condition * Seasonal affective disorder * Substance abuse * Substance dependence 3 months prior * A psychotic disorder including schizoaffective disorder, bipolar disease, borderline personality disorder or major depression with psychotic features * Neurological disorders, including a history of seizures, cerebrovascular disease, primary or secondary tumors in CNS, cerebral aneurysm, dementia, or movement disorders * Ongoing intake disorders such as bulimia or anorexia, or intake disorder in the past fiscal year * History of increased intracranial pressure or head trauma * Nursing * Any other disease or condition at the investigator's discretion that may pose risk to the patient or compromise the study * Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes. Failure to follow this restriction could result in serious injury or death. Certain exceptions apply to mouth implants, such as standard amalgam dental fillings, single post dental implants, dental bridge work, and braces. If these items are present, the therapy can still be administered. * By means of decompensation, it means a patient with a proven medical history of a decompensated health condition and long-term medication. Patients who use certain medications only for preventive purposes, without any proven previous health condition failure, are not considered contraindicated. * Defined by a score of Level 4 or Level 5 on the Columbia-Suicide Severity Rating Scale (CSSRS).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Generalized anxiety disorder (GAD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Aria Integrative Health
RECRUITINGDenver, Colorado, 80211, United States
-
Cady Wellness Institute
RECRUITINGNewburgh, Indiana, 47630, United States
-
The Study by AC
RECRUITINGChicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can the right electric pulse calm chronic worry?
- A brief therapy that builds on strengths may calm young adult anxiety
- Can brain and blood data predict Anxiety's future?
- Can a daily microdose of psilocybin calm chronic anxiety?
- Can online therapy or parent coaching ease childhood anxiety? a head-to-head trial aims to find out.
- Brain zapping without surgery: new device targets deep brain regions to treat depression and anxiety